prostaglandin E2 EP4 receptor inhibitor AN0025

{
  "id": "MLC-T-ONC-016251",
  "term": "prostaglandin E2 EP4 receptor inhibitor AN0025",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable antagonist of the prostaglandin E2 (PGE2) receptor type 4 (EP4; EP-4), with potential immunomodulating and antineoplastic activities. Upon oral administration, AN0025 selectively targets, binds to and blocks the activity of immunosuppressive tumor-associated myeloid cells (TAMCs) in the microenvironment. This abolishes TAMC-dependent immunosuppression and reduces tumor cell proliferation. The presence of immunosuppressive myeloid cells in certain tumors is associated with a poor prognosis.",
  "synonyms": [
    "EP4 inhibitor E7046",
    "EP4 antagonist E7046",
    "prostaglandin E EP4 receptor antagonist E7046"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/prostaglandin-e2-ep4-receptor-inhibitor-an0025/"
}